TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03581513

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deferred or Immediate Stent Implantation
Description: IMR can be used to measure the microcirculatory resistance of coronary artery. It is not clear whether the IMR value could determine the time of PCI for STEMI patients.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deferred or Immediate Stent Implantation
Description: IMR can be used to measure the microcirculatory resistance of coronary artery. It is not clear whether the IMR value could determine the time of PCI for STEMI patients.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deferred or Immediate Stent Implantation
Description: IMR can be used to measure the microcirculatory resistance of coronary artery. It is not clear whether the IMR value could determine the time of PCI for STEMI patients.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deferred or Immediate Stent Implantation
Description: IMR can be used to measure the microcirculatory resistance of coronary artery. It is not clear whether the IMR value could determine the time of PCI for STEMI patients.
Study: NCT00943488

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated H1N1 Vaccine
Description: Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly as 15 or 30 mcg per dose.
Study: NCT01346176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advance Directive Forms
Description: Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, they will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advance Directive Forms
Description: Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, they will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advance Directive Forms
Description: Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, they will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.
Study: NCT00914576

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin and mineral supplement
Description: 1 capsule/day in the morning for 14 days, containing: Lutein 12mg, Vitamin C 300mg, Zinc 10mg, Ginko Biloba 10mg, Flavonoids 25mg, Fish oil 300mg
Study: NCT02475395

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRAK device
Description: Use of TRAK to attain sperm concentration measurement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRAK device
Description: Use of TRAK to attain sperm concentration measurement
Study: NCT05877651

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MASCT-I injection
Description: The final products of MASCT-I technology are dendritic cells (DC) and effector T cells
Study: NCT02366754

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Repetitive TMS is a non-invasive neural stimulation technique achieved via electromagnetic induction. An insulated metal coil is placed on the scalp and short discharges of electric current are directed through the coil producing a magnetic field. This magnetic field is accompanied by an electric field that passes through the skull inducing currents in the tissue beneath the coil. If a cell beneath the coil is viable, then rTMS initiates or inhibits an action potential affecting ongoing neural activity. 30 sessions of active rTMS are provided.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo rTMS
Description: The placebo coil simulates magnetic stimulation, but does not actually emit a pulse. The placebo coil looks, sounds and feels like an active rTMS coil. The placebo coil, visually identical to the active coil, provides a slight sensory sensation and discharge noise (i.e., clicking) nearly identical to that of the active coil.
Study: NCT00663455

Intervention type: DRUG
Group type: OTHER
Intervention: Reduction of cyclosporine A (CSA)-dosing
Description: Reduction of CSA-dosing over 4 months. Therapy control by safety parameters (serum creatinine, C2-monitoring, renal biopsy).
Study: NCT02280941

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: single photon emission computed tomography
Description: Single photon emission computed tomography (SPECT) imaging will be done.
Study: NCT04379219

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: giving methotrexate at least 1 w week before surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: giving methotrexate at least 1 w week before surgery
Study: NCT02083926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine (a single 0.5mg/kg intravenously over 40 minutes).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: Saline (a single 0.5mg/kg intravenously over 40 minutes).
Study: NCT03614494

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piroxicam 40 mg
Description: Additional co-treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel 1.5mg
Description: Standard treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levonorgestrel 1.5mg
Description: Standard treatment
Study: NCT05421104

Intervention type: OTHER
Intervention: Ruxolitinib
Description: PV patients who were resistant to or intolerant of HU (as defined on the index date) and switched to RUX in the post-index period.
Study: NCT02306057

Intervention type: PROCEDURE
Intervention: Pre BCPC
Description: Routine catheterization before surgical procedure Bidirectional CavoPulmonary Connection

Intervention type: PROCEDURE
Intervention: Pre TCPC
Description: Routine catheterization before surgical procedure Total CavoPulmonary Connection

Intervention type: PROCEDURE
Intervention: BCPC surgery
Description: Surgical procedure Bidirectional CavoPulmonary Connection

Intervention type: PROCEDURE
Intervention: TCPC
Description: Surgical procedure Total CavoPulmonary Connection
Study: NCT01344382

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Reinforcement and Family Training
Description: The philosophy of Community Reinforcement and Family Training (CRAFT) is that drug abuse is caused by multiple biological and environmental factors, many of which are beyond the parents' control. However, because parents have an important relationship with their child, they may able to influence his or her behavior. CRAFT for parents (CRAFT-P) will teach the parent new ways to interact with their child. Sessions will be designed to build the parents' motivation to comply with the training, conduct a functional analysis of their child's drug use pattern, train methods of behavior management and communication skills, enrich the parent's life and to suggest and motivate treatment entry.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Al-Anon Facilitation
Description: Al-Anon Facilitation (ANF) parallels the Twelve Step Facilitation intervention developed by Nowinski et al. (1992) for Project MATCH. The content focuses on introducing parents to Alanon or Naranon's purpose and philosophy, educating about 12-step concepts, the fellowship community, denial and enabling, acceptance, caring detachment, and surrendering to a higher power. The trainer's role is to help the parent to gain insight into the ways they interact with their child and to educate and encourage the parent to become actively involved in a 12-step community and to take advantage of its many offerings.
Study: NCT00766155

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study: NCT03313648

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Hepatectomy
Description: 180 patients with recurrent HCC with recurrent nodular diameters of less than 5 cm and up to three nodules were randomly divided into LH (n=90) and RFA groups (n=90). Outcomes were monitored and evaluated during the 5-year follow-up period.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Ablation
Description: 180 patients with recurrent HCC with recurrent nodular diameters of less than 5 cm and up to three nodules were randomly divided into LH (n=90) and RFA groups (n=90). Outcomes were monitored and evaluated during the 5-year follow-up period.
Study: NCT00702208

Intervention type: DEVICE
Group type: OTHER
Intervention: Delphi Screener
Description: Self-sampling device for cervical vaginal lavage
Study: NCT01842126

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BG00010 IV
Description: Ascending Doses intravenous (IV) of BG00010

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BG00010 SC
Description: Ascending Doses subcutaneous (SC) of BG00010

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BG00010 SC
Description: Ascending Doses subcutaneous (SC) of BG00010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo IV
Description: Ascending Doses intravenous (IV) of Placebo
Study: NCT00914576

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin and mineral supplement
Description: 1 capsule/day in the evening for 14 days, containing: Zeaxanthin 5mg, Vitamin E 60mg, Copper 1mg, Selene 20µg, Ginko Biloba 10mg, Flavonoids 25mg, Alpha Lipon acid: 150mg
Study: NCT01842126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo SC
Description: Ascending Doses subcutaneous (SC) of placebo
Study: NCT00914576

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules/day for 14 days
Study: NCT02163252

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Intervention
Study: NCT01495624

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ropivacaine plus dexamethasone anesthetic
Description: Subjects will receive interscalen block comprised of 30 ml 0.5% ropivacaine plus dexamethasone 8 mg (2 ml) mixed with the local anesthetic with 2 ml normal saline given intravenously (systemic placebo);

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine plus saline plus dexamethasone anesthetic
Description: Subjects will receive interscalen block with 30 ml 0.5% ropivacaine for interscalene block mixed with 2 ml normal saline (perineural placebo) plus dexamethasone 8 mg (2 ml) administered systemically.
Study: NCT00124878

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Male circumcision
Description: Sleeve circumcision

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Male circumcision
Description: Sleeve circumcision
Study: NCT01616459

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine GSK2830929A
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine GSK2830930A
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Synflorix™
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13™
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa™
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa™
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix hexa™
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix hexa™
Description: Intramuscular injection
Study: NCT03964376

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasal High Flow
Description: Delivery of oxygen via OptiflowTM system (AirvoTM, Fisher \& Paykel Inc.) with airflow of 20 to 50 Litre/minute

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Delivery of oxygen at 2-4 Litre/minute via nasal cannula or 6 Litre/minute via face mask
Study: NCT00376519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Cyclophosphamide 60 mg/kg/day will be administered as a 2 hour intravenous infusion with a high volume fluid flush and mesna (MT(S)9006) on day -8 and -7 one hour after fludarabine infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Will be administered beginning on day -3 and adjusted to maintain a level of \>200. For adults the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours.
Study: NCT00914576

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100% Oxygen
Description: breathing of 100% O2 for 30 minutes on both study days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 100% Oxygen
Description: breathing of 100% O2 for 30 minutes on both study days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escherichia coli Endotoxin
Description: Escherichia coli Endotoxin (LPS, US Standard Reference Endotoxin, dose: 2 ng/kg bodyweight (corresponding to 20 IU/kg), i.v. bolus on both study days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escherichia coli Endotoxin
Description: Escherichia coli Endotoxin (LPS, US Standard Reference Endotoxin, dose: 2 ng/kg bodyweight (corresponding to 20 IU/kg), i.v. bolus on both study days.
Study: NCT02494934

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive-behavioural therapy
Description: The CBT program was adapted from a previously used group CBT program and included the following procedures: (1) education about PVD; (2) collaborative re-conceptualization of PVD as a multi-factorial pain condition; (3) desensitization exercises; (4) diaphragmatic breathing and other relaxation techniques; (5) discussion about and techniques for increasing sexual desire and arousal; (6) sexual communication skills training; (7) instructions on carrying out PFM exercises; (8) instructions on the use of silicone vaginal dilators to do progressive vaginal penetration activities at home; and (9) informal and formal cognitive restructuring techniques and the use of coping self-statements.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical therapy
Description: The PT treatment protocol included the following procedures: (1) education about PVD; (2) targeted PFM exercises focused on contraction and relaxation including in-session practice and feedback; (3) manual techniques; (4) surface electromyographic biofeedback (sEMG); (5) progressive vaginal penetration activities through the use of four silicone vaginal dilators of varied diameter; (6) stretches of the hip muscles; (7) deep breathing and global body relaxation exercises; and (8) additional methods of managing pain and counseling about different sexual positions.
Study: NCT01347658

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Echinacea purpurea
Description: Patients will take Echinacea purpurea (500 mg every 8 hours) during 14 days.
Study: NCT01862393

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 400 microseconds
Description: Neuromuscular electrical stimulation with stimulus phase duration of 400 microseconds
Study: NCT01987076

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone:~Day 0 to day 30: 0.5mg/kg/day Day 30 to day 180: doses decreasing from 15 to 25% every 15 days until Day75 and 10 to 15% every 15 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol
Description: Clobetasol: cream 0.05% Day 0 to day 30: 30 grams per day Day 30 to day 45: 20 grams per day Day 45 to day 60: 20 grams every other day Day 60 to day 120: 20 grams biweekly Day 120 to day 150: 20 grams one a week
Study: NCT02363842

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pressure redistribution surface
Description: Standard of Care (SOC): pressure redistribution surface already in use at the participating institution to manage patients at risk for tissue breakdown
Study: NCT02057731

Intervention type: GENETIC
Intervention: Glycogen Storage Disease markers
Description: Blood and urine tests will be performed on all groups to measure markers of GSD. A saliva DNA test will be used to determine the specific mutation the carrier has or to ensure noncarrier status. A questionnaire will also be filled out.
Study: NCT00376519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Fludarabine 25 mg/m\^2/day will be administered as a 1 hour intravenous infusion on days -9 through -7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: All patients will begin mycophenolate mofetil (MMF) on day -3, at the dose of 3 grams/day divided into 2 or 3 doses (every 12 or 8 hours).
Study: NCT01862393

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 700 microseconds
Description: Neuromuscular electrical stimulation with stimulus phase duration of 700 microseconds

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1000 microseconds
Description: Neuromuscular electrical stimulation with stimulus phase duration of 1000 microseconds
Study: NCT00376519

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treg cell infusion
Description: On day -1 prior to UCB transplantation, Treg cells will be infused IV without in-line filtration. A semi-log dose escalation of CD4+CD25+ Treg cells is scheduled with 3 patients at each step. Doses will be 0.1 x 10\^6/kg, 0.3 x 10\^6/kg, 1 x 10\^6/kg and 3 x 10\^6/kg weight (determined on the day prior to administration of the preparative therapy).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation
Description: Following the administration of the preparative therapy, all subjects will undergo UCB transplantation. The UCB will be administrated by IV infusion without in-line filtration.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Radiotherapy: 165 cGy will be administered on day -5 through -2 two fractions each day.
Study: NCT01366443

Intervention type: PROCEDURE
Intervention: Sterile speculum exam
Description: Sterile vaginal speculum exam to include Nitrazine, ferning and pooling observations

Intervention type: PROCEDURE
Intervention: ROM Plus Exam
Description: Vaginal swab exam for ROM Plus Test

Intervention type: PROCEDURE
Intervention: Chart Reveiw
Description: Post delivery blinded chart review by expereienced obstetrician
Study: NCT04616911

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rerouting seton
Description: Excision of superficial fistula tract and placment of seton with rerouting of the fistula tract around the internal anal sphincter
Study: NCT03520816

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Burn Physiotherapy Protocol
Description: It consisted of parameters such as early mobilisation and ambulatory training, chest physiotherapy, and both active and passive normal joint movement exercises.
Study: NCT00885417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cravit-based sequential therapy
Description: Eligible patients will be treated with (esomeprazole 40mg bid +amoxicillin 1gm bid) for 5 days, followed by (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid ) for another 5 days
Study: NCT04191967

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermocoagulation
Description: Treatment of positive screening results will be performed using the Liger Thermocoagulator device
Study: NCT02815241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987517
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z43-046)
Study: NCT00878215

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Explorer Liver Image Guided System

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Explorer Liver Image Guided System
Study: NCT03444272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and Daklatasuvir
Description: HCV Treatment (Sofosbuvir and Daklatasuvir)
Study: NCT00118378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: 50 mg per day, increasing to 200 mg per day as clinically indicated

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 mg per day, increasing to 200 mg per day as clinically indicated
Study: NCT01371084

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Pedal@Work Worksite Wellness
Description: Participants randomized to the intervention group will be provided access to a portable pedal exercise machine, a pedometer and a worksite wellness motivational website for 12 weeks. As part of this website, participants will be emailed behavioral intervention materials a maximum of three times per week targeted at reducing sedentary time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pedal@Work
Description: Worksite wellness program.
Study: NCT03351387

Intervention type: COMBINATION_PRODUCT
Intervention: SPY Intra-operative Angiography
Description: The SPY Intra-operative Angiography Fluorescent Imaging System consists of an imaging head equipped with a charged coupled device (CCD) camera, a laser light source and a distance sensor. The imaging head is attached to an articulating arm on a mobile cart containing the central processing unit, keyboard, monitor, and mouse. SPY is used in tandem with indocyanine green (ICG), a water-soluble tricarbocyanine dye. Once the camera is in place, 5 cc of diluted ICG is pushed through an IV line and is flushed immediately; simultaneously the room lights must be dimmed. Perfusion images will be recorded then the SPY system will be removed from the operating room.